Prerpints.org logo
Preprint
Review

Enhancing Dendritic Cell Cancer Vaccination: The Synergy of Immune Checkpoint Inhibitors in Combined Therapies

Altmetrics

Downloads

143

Views

52

Comments

0

A peer-reviewed article of this preprint also exists.

supplementary.zip (4.51MB )

Submitted:

12 June 2024

Posted:

13 June 2024

You are already at the latest version

Alerts
Abstract
Dendritic cell (DC) cancer vaccines are a promising therapeutic approach, leveraging the immune system to fight tumors. These vaccines utilize DCs' ability to present tumor-associated antigens to T cells, triggering a robust immune response. DC vaccine development has progressed through three generations. The first generation involved priming DCs with tumor-associated antigens or messenger RNA outside the body, showing limited clinical success. The second generation improved efficacy by using cytokine mixtures and specialized DC subsets to enhance immunogenicity. The third generation uses blood-derived DCs to elicit a stronger immune response. Clinical trials indicate that cancer vaccines have lower toxicity than traditional cytotoxic treatments. However, achieving significant clinical responses with DC immunotherapy remains challenging. Combining DC vaccines with immune checkpoint inhibitors (ICIs) such as anti-cytotoxic T-lymphocyte Antigen 4 and anti-programmed Death-1 antibodies has shown promise by enhancing T cell responses and improving clinical outcomes. These combinations can transform non-inflamed tumors into inflamed ones, boosting ICIs' efficacy. Current research is exploring new checkpoint targets like LAG-3, TIM-3, and TIGIT, considering their potential with DC vaccines. Additionally, engineering T cells with chimeric antigen receptors or T cell receptors could further augment the anti-tumor response. This comprehensive strategy aims to enhance cancer immunotherapy, focusing on increased efficacy and improved patient survival rates.
Keywords: 
Subject: Medicine and Pharmacology  -   Oncology and Oncogenics

1. Introduction

Cancer continues to be a significant global challenge, leading to over 9 million deaths in 2020 alone.
Traditional treatments, such as chemotherapy, radiation, and surgical interventions, have significant limitations and side effects, prompting the search for more innovative strategies. One promising approach involves cancer vaccination, using dendritic cells (DCs) to trigger the body's immune response against tumors. [1,2,3].
Dendritic cells, key players in the human immune system, display a rich diversity in their composition. This includes the conventional CD11C+ DCs (cDCs), with subsets such as cDC2 (CD1C+) and cDC1 (CD141+), along with the CD11C- plasmacytoid DCs (pDCs) characterized by CD123+ and CD303+ cells. There's a well-documented association between various diseases, including cancers, and alterations in DC populations, either through a decrease in numbers or impaired functionality. Mature DCs are crucial for initiating the body's immune defense against cancers by identifying and activating effector cells of the adaptive immune system. They are particularly adept at presenting Tumor Associated Antigens (TAAs) to T lymphocytes, thereby facilitating adaptive anti-cancer responses [4,5,6].
The tumor microenvironment can have a negative impact on DC maturation and function, leading to a state of tolerance that weakens the immune system's ability to fight tumors. An efficient DC-based cancer vaccine must have both efficient TAA presentation and co-stimulating molecules to overcome the tumor's immunosuppressive effects [4,5,6]. The ultimate objective is to harness DCs' inherent capacity to penetrate tumors and elicit a robust immune response that involves T lymphocytes and natural killer (NK) cells [4,5,6,7]. Over recent years, DCs have emerged as a cornerstone of cancer immunotherapy, leading to the development of more effective clinical protocols and positioning DC-based vaccines at the forefront of this critical area of research [1,3,6]

2. DC-Based Cancer Immunotherapy

The last decade has witnessed significant efforts in refining DC vaccines technology. With more than 200 clinical trials targeting various cancers, including melanoma, prostate cancer, glioblastoma, and renal cell carcinoma, the advancements are noteworthy [8,9]. The development of DC vaccines can be categorized into three "generations."
The first generation of DC vaccines was initially produced ex vivo from sources such as peripheral blood mononuclear cells (PBMCs), monocyte-derived DCs (MoDCs), or CD34+ hematopoietic progenitors.
These cells were then primed with tumor-associated antigens (TAAs) or messenger RNA (mRNA) encoding these antigens [10]. While this method was confirmed to be safe, its clinical efficacy was limited, with a reported tumor regression rate of only 3.3%. [8,11]. This prompted a shift towards more sophisticated approaches in subsequent generations, aiming to enhance the efficacy of DC-based cancer vaccines by improving antigen presentation and the induction of a robust immune response against tumors.
The second-generation DC vaccines were developed to boost their immunogenicity by maturing and activating specific DC subsets using cytokine cocktails and pathogen-derived molecules.
This generation notably incorporated TAAs such as peptides from melanoma-associated antigens, Wilms tumor 1 (WT1), New York esophageal squamous cell carcinoma 1 (NY-ESO-1), and even whole tumor cell lysates [9]. The increased effectiveness of these DC vaccines is largely due to their utilization of more specialized DCs adept at presenting antigens through Major Histocompatibility Complex (MHC)-I/II and initiating cytotoxic T lymphocyte (CTL) responses [12]. Specifically, pDCs are highlighted for their proficiency in Type I interferon (IFN) responses, while cDCs are recognized for their enhanced ability in engulfing dying cells and presenting antigens [13,14]. The strategic utilization of CD1c+ cDCs and CD141+ cDCs, both recognized for their high capacity for MHC-dependent antigen presentation, significantly enhances the proliferation of CTLs and the generation of CD8+ memory T cells, respectively [15].
Early clinical trials have shown objective responses in 5% to 15% of cancer patients receiving these vaccines, along with indications of improved survival rates [8]. However, a major challenge remains persist in consistently generating DCs that effectively target stable tumor antigens effectively and activate tumor-killing T cells across the various patients.

3. The Next Generation of DC-Based Vaccination

The field of DC-based vaccination is rapidly advancing, with a significant move towards using DCs directly sourced from the bloodstream. According to this approach, blood-derived DC subsets may cause a stronger immune response than those produced in vitro. An example of this is the intranodal injection of activated human pDCs combined with TAA peptides, which has been shown to induce significant T cell responses in metastatic melanoma patients [16]. Clinical trials in prostate cancer and melanoma have not only confirmed the safety and feasibility of using blood-derived cDC2s CD1c+ with TAA peptides but also suggested an improvement in progression-free survival rates. Specifically, the use of autologous CD1c+ DCs has been linked to long-term progression-free survival (12–35 months) in a subset of melanoma patients [17,18]. Additionally, a study using autologous pDCs loaded with TAA peptides in melanoma patients reported antigen-specific CD4+/CD8+ T-cell responses and a measurable IFN signature [16].
Progress in DC vaccines also extends beyond the choice of cell type, with significant efforts focused on the precise selection of immunizing antigens. Attention is particularly focused on tumor-specific neoantigens, unique peptides resulting from somatic mutations absent in normal cells.
These neoantigens represent a promising target for enhancing the specificity and efficacy of DC vaccines [1]. In a phase I clinical trial focused on patients with advanced melanoma, the use of DC vaccinations, loaded with neoantigenic mutant peptides of high affinity and tailored to the individual profiles of the patients, has shown promising results. These vaccines have been successful in initiating neoantigen-specific T cell responses, leading to disease stabilization or non-recurrence in some cases [19]. However, the variability and limited occurrence of neoantigens across different cancers and among patients present significant challenges. This variability necessitates the careful selection of inducers that are not only specific to the type of cancer but also, when possible, to the genetic makeup of the individual patient. Additionally, there are concerns about the potential for cross-reactivity with non-mutated proteins, which could trigger autoimmunity [20,21]. Nevertheless, more clinical insights are required to understand the potential efficacy of neoantigens-based DC vaccines.
Neoantigens can be introduced to DCs using various methods, such as pulsing with synthetic peptides, using autologous whole tumor lysate (WTL), or fusing with tumor cells, as well as pulsing with whole mRNA from autologous tumors.
Approaches utilizing the whole tumor cell have served as polyvalent sources of TAAs, capable of triggering a more comprehensive immune response [22,23]. This strategy aims to bypass the challenge of antigen selection by including a broad array of TAAs, including patient-specific neoantigens [22,23,24].
Early clinical trials have shown that in order to effectively stimulate an antigen-specific immune response when encountering T-cells, DCs need to be in a "mature" state [25].
Among the methods for introducing neoantigens into DCs, mRNA transfection stands out for its simplicity in generating intracellular neoantigens. Beyond just introducing neoantigens, mRNA electroporation can also incorporate functional proteins into the DCs, providing further activation and maturation signal [26]. Vaccines loaded with whole tumor mRNA have been shown to elicit specific T cell responses against neoantigens and have been proven safe across a variety of tumors, including melanoma, renal, prostate, uterine and ovarian, colorectal, pancreatic cancers, multiple myeloma, and Acute Myeloid Leukemia (AML) [27].
Cancer vaccines have demonstrated minimal toxicity in clinical trials compared to other cytotoxic therapies, encouraging the continued exploration of this immunotherapeutic strategy across various cancer types. However, achieving objective clinical responses with DC immunotherapy remains an elusive goal for specific cancer types [28,29,30,31].

4. Immune Checkpoint Inhibitors

Immune checkpoint inhibitors (ICIs) represent a novel class of immunotherapeutic agents that enhance the response of antitumor-specific T cells in a broad range of malignancies. The most commonly targeted molecules for their therapeutic potential include Cytotoxic T-Lymphocyte Antigen (CTLA)-4, Programmed Death 1 (PD-1), and Programmed Death- ligand 1 (PD-L1) [32,33,34]. Pembrolizumab and nivolumab are examples of anti-PD-1 monoclonal antibodies, while atezolizumab targets PD-L1, showcasing the breadth of strategies employed to bolster the immune system's ability to fight cancer [35]. Immune checkpoint inhibitors have proven to be effective anticancer agents in the treatment of various cancers, including melanoma, lung cancer, bladder cancer, head and neck cancers, and Hodgkin and non-Hodgkin lymphoma [24,36,37,38,39]. Tumors with elevated mutational loads, such as melanoma and lung cancer, and those with a high frequency of mutational lesions, tend to respond better to ICI treatment [24,36,40]. This is because a higher tumor mutational burden leads to increased neoantigen load, which enhances the likelihood of generating immunogenic neoantigens. Notably, the activity of neoantigen-directed T cells in tumors that regress following ICI treatment has been a significant observation [41]. ICIs treatment is particularly effective in tumors with an immune-inflamed phenotype, characterized by immune cell infiltration at the tumor edge or within the tumor stroma, indicating an inflammatory tumor environment. Conversely, patients with “non-inflamed” tumors and low neoantigen burdens may not respond as well to ICIs, underscoring the need for complementary strategies to enhance tumor-infiltrating lymphocytes [24,36,42,43]. In addition the biology of specific tumors represents a critical aspect to be taken into account. As an example tumor cells of Hodgkin lymphoma and of Primary Mediastinal B-cell lymphoma typically harbor structural alterations at chromosome 9p24.1, leading to the stable overexpression of PD-L1 and PD-L2 [44,45]. Consequently, PD1-blockade has emerged as a major therapeutic strategy for both these malignancies [46,47].
The high clinical response rates achieved by ICIs have prompted the consideration of next-generation DC vaccines in oncology. DC-based cancer vaccines could play a crucial role in the success of ICI treatments by converting “non-inflamed” non-permissive tumors into “inflamed” tumors, thereby priming and recruiting intratumoral T cells.

5. ICIs in Combination with DCs Based Cancer Vaccination

DC vaccines ensure the antigen-specificity of the immune response, while checkpoint blockade further amplifies it. Combining these approaches could enhance T cell priming through the DC vaccine, especially when used with anti-CTLA-4 monoclonal antibodies, or prevent the exhaustion of vaccine-induced responses when paired with anti-PD-1 monoclonal antibodies. Preliminary in vitro data support the hypothesis of a synergistic effect between checkpoint blockade and DC vaccination [48,49].
Figure 1 summarizes the several approaches combining DC-based cancer vaccines with adjunctive strategies.

5.1. Anti-CTLA4 Antibodies

The data indicate that autologous DCs, pulsed with the Melanoma Antigen Recognized by T cells 1 (MART-1) peptide, were administered alongside escalating doses of Tremelimumab (an anti-CTLA-4 antibody) to 16 patients with advanced melanoma. This treatment regimen was feasible and well-tolerated, with manageable dose-limiting toxicities. Antigen-specific T cell responses were detected in 11 patients using MHC tetramer and Enzyme-Linked immuno SPOT (ELISPOT) assays. Additionally, gene expression profiling revealed that responders exhibited baseline overexpression of genes related to B-cell functions. In total, four patients showed objective tumor responses, with two achieving partial responses and two achieving complete responses. These results suggest that combined immunotherapy offers a higher response rate compared to either single agent alone [32]. A subsequent phase II study in patients with pretreated advanced melanoma confirmed these promising results. This trial combined autologous DCs pulsed with melanoma-associated antigens (TriMixDC-MEL) and the CTLA-4-blocking antibody Ipilimumab. The combination significantly enhanced T cell stimulation, as demonstrated by increased Human Leukocyte Antigen (HLA)-DR expression and cytokine secretion in CD4+ T cells. The overall response rate was 38%, with eight patients achieving complete responses and seven achieving partial responses. The median follow-up for patients who responded was 36 months [50]. These findings indicate that Ipilimumab administration following the DC vaccine effectively boosts tumor-specific T-cell responses [54]. Furthermore, the combination of the Mucin-1 (MUC1)-mRNA DC vaccine with CTLA-4 blockade outperformed either the DC vaccine or CTLA-4 blockade alone in patients with triple-negative breast cancer (TNBC) [51] (Figure 1).

5.2. Anti-PD-1 Antibodies

Monotherapy with anti-PD-1 is insufficient to suppress tumor growth, whereas combining anti-PD-1 treatment with a DC vaccine significantly suppresses melanoma growth in animal models [52]. Similarly, the Human Epidermal Growth Factor Receptor 2 (HER2)-DC1 vaccine, when combined with anti-HER2 therapy and anti-PD-1, induces infiltration of both CD4 and CD8 T cells into tumors, leading to increased survival in preclinical models of HER2-positive breast cancer [53]. These findings align with reports that anti-PD-1 administration can enhance the efficacy of DC-based vaccines [54]. In this regard, data from multiple myeloma (MM) patients, as reported by Rosenblatt et al., show that PD-1 blockade enhances ex vivo T cell responses to DC vaccines in MM. Specifically, the anti-PD-1 antibody (CT-011) combined with autologous DCs fused with myeloma cells (DC/MM fusion) increases Th1 cytokine secretion, limits regulatory T cells (Treg) expansion, and improves tumor cell killing [55] (Figure 1). Furthermore, a pilot study involving seven patients with stage IV pancreatic cancer found that low systemic doses of the anti-PD-1 antibody are more effective when paired with DC vaccination [56]. While clinical data is still pending, ongoing early-phase trials are actively investigating this synergistic approach with PD-1 blockade. One clinical study is assessing the effects of this combination strategy on MM patients compared to autologous transplantation no alone. In this study, MM patients will receive serial infusions of the CT-011 antibody combined with the DC/myeloma fusion vaccine following autologous transplantation (NCT01067287).
Treatment with anti-PD-L1 can notably aid in the maturation of DCs and enhance the functionality of the DC1 subtype. This approach may also increase the number of activated cytotoxic T lymphocytes (CTLs) with strong anti-tumor properties. Consequently, combining DC vaccines with anti-PD-L1 could be a promising strategy for cancer therapy [57]. In a single-arm study (NCT02528682), researchers evaluated the effect of a PD-L1/L2-silenced, antigen-loaded DC vaccine in MM. The DCs vaccine demonstrated minimal side effects, and no participants developed graft-versus-host disease (GVHD).
Genetic engineering is an option to deactivate ICI in the DC vaccine [58,59]. Currently, a clinical trial is examining the use of PD-L1/L2 silenced moDC in the post-transplant phase for various hematological malignancies (NCT02528682). This approach aims to prevent immune-related adverse events associated with checkpoint inhibitor therapy [60], but may be less efficient as it will not prevent the inhibition of T cells by ligands expressed on leukemic cells [61].
Using patient-specific DCs combined with AML cells, a personalized cancer vaccine strategy showed promising results in stimulating anti-leukemic immune reactions, emphasizing the possibility of tailored vaccine treatments for AML patients once hematologic remission has been achieved [62]. This led to the initiation of a clinical trial to evaluate the effectiveness of AML DC hybrid vaccines, in combination with blockade of PDL-1/PD-1 pathway, in a multicenter study performed in 63 AML subjects enrolled in April 2024 (NCT01096602).
A phase I/II trial (NCT03035331) is currently assessing the feasibility and efficacy of combining DCs therapy with cryosurgery and Pembrolizumab in 11 Non Hodgkin Lymphoma (NHL) patients enrolled as to April 2024. Cryosurgery works by freezing cancer cells, while immunotherapy involving monoclonal antibodies like pembrolizumab aims to enhance the body's immune system in fighting the cancer and may interfere with the ability of tumor cells to grow and spread. A phase I/II trial is currently assessing the feasibility and efficacy of DC therapy in combination with cryosurgery and Pembrolizumab for patients with stage III-IV Melanoma that is not surgically removable (NCT03325101).
Furthermore, in a phase II trial involving patients with Follicular lymphoma (FL), a sequential intranodal immunotherapy (SIIT) approach is being utilized in conjunction with Pembrolizumab. This treatment method includes radiotherapy alongside ultrasound-guided injections of autologous DCs, rituximab, and Granulocyte-Macrophage colony-stimulating factor (GM-CSF) (NCT02677155).
Ongoing clinical trials are illustrated in Table 1.

6. Novel Checkpoint Targets

Recent research has been exploring novel checkpoint molecules for potential use in anticancer immunotherapy. These include T-cell immunoglobulin and mucin-containing protein-3 (TIM-3), lymphocyte activation gene-3 (LAG-3), and T cell immunoglobulin and ITIM domain (TIGIT). They function as inhibitors of T-cell activation and are considered encouraging targets for therapy (FIGURE 1).
Blocking specific molecules alongside PD-1 on CD8 tumor-infiltrating lymphocytes (TILs) has been shown to be more effective than solely focusing on PD-1 in several studies. Based on preliminary research, blocking these pathways may enhance anti-tumor T cell immune responses, possibly preventing tumor growth in solid tumors and hematologic neoplasms [63,64,65]. Advanced-stage melanoma patients were involved in a clinical trial where a combination therapy was administered. This therapy consisted of a MART-1 peptide-based vaccine and a LAG-3-Ig fusion protein (IMP321) targeting LAG-3's natural ligand. IMP321 acts as a new adjuvant, triggering strong antigen-specific CD8 T-cell responses. While the trial did not show any objective clinical responses, it did reveal strong and long-lasting antitumor immune reactions in patients who were given IMP321. More specifically, there was a notable rise in tetramer-reactive MART-1 CD8+ T cells, and a reduction in the levels of adaptive regulatory T cells (Tregs) [66]. The combination of these new checkpoint inhibitors with DC-based vaccines holds promise for improving immunogenicity and clinical efficacy, thus presenting hopeful possibilities for better clinical care of cancer patients.
Recent data shows that blocking LAG-3 greatly enhances T cell priming by DCs. This suggests that a potential promising treatment approach for malignancies with weak immune responses, like AML, could be the combination of a DCs vaccine with anti-LAG-3 monoclonal antibodies [67]. Additionally, co-inhibition of PD-1, TIGIT, and TIM-3 following DC vaccination has been shown to stimulate CD8+ T cell-mediated immune responses in gastric cancer models [68].

7. Enhancing the Efficacy of Combination Strategies with ICIs trough Engineered T Cells

Autologous T cells engineered with T cell receptors (TCRs) or chimeric antigen receptors (CARs) exhibit potent activation, specifically targeting and eliminating cancer cells. This innovative approach presents a compelling option for the treatment of various neoplasms. Clinical trials have validated the effectiveness of TCR- and CAR-engineered T cells in the treatment of diverse cancer types [69,70,71]. Expanding on these breakthroughs, a novel strategy could involve synergizing DC-based cancer vaccines with engineered T cells to amplify T cell responses against tumor-associated antigens (TAAs). This combined approach holds promise in enhancing immune reactions against TAAs with limited immunogenicity (Figure 1).
In this regard, a pilot clinical trial has employed CAR-DCs containing a scFv domain targeting EphA2 antigen, loaded with TP53 mutant peptide (TP53-EphA-2-CAR-DC) in combination with ICIs to assess the safety and antitumor effects in subjects with local advanced/metastatic solid tumors or relapsed/refractory (R/R) lymphomas (NCT05631886).
Table 1 shows the ongoing clinical trials.
Figure 2 illustrates how checkpoint inhibitors promote anti-tumor specific T cells responses.

8. Conclusions

Recent clinical trials and research have validated the safety and feasibility of DC-based cancer vaccinations. However, the effectiveness of these vaccines in clinical settings is often hindered by the immunosuppressive nature of the tumor microenvironment (TME). The focus of current efforts is to unravel and reverse the complex interactions in the TME that disrupt immune function, impair T cell activation, and prevent efficient cancer cell killing in tumors.. Researchers are delving into various aspects of immune dysregulation to optimize T cell function by employing advanced techniques for the generation, activation, maturation, in vivo targeting, antigen loading of DCs, and personalized mapping of neoantigens. The future of cancer immunotherapy is likely to revolve around the integration of these critical elements. This has led to an upsurge in clinical investigations that explore combining DC vaccinations with immunomodulatory agents, especially ICIs, to enhance therapeutic efficacy. Additionally, the potential synergy between DC-based cancer vaccination and cutting-edge immunotherapy approaches, such as CAR T cell therapy, is being explored to amplify the anti-tumor immune response. The integration of multiple immunotherapeutic modalities has demonstrated improved efficacy and tolerability in clinical trials and shed light on the complex landscape of cancer immunology. Identification of novel immune checkpoint molecules and the development of monoclonal antibodies against them hold promise in enhancing the efficacy of DC-based cell therapy for cancer patients, although further clinical studies are warranted for translation into practice. Moreover, the convergence of next-generation sequencing (NGS) and bioinformatics tools is revolutionizing cancer immunotherapy by enabling the identification of tumor-specific neoantigens that can be utilized to design personalized DC vaccines. Furthermore, advancements in nanotechnology are being harnessed to optimize the delivery and efficacy of DC vaccines. Engineered nanoparticles offer improved stability and bioavailability of antigens and adjuvants, facilitating targeted delivery to DCs and stimulating robust immune responses.
In conclusion, the future landscape of cancer immunotherapy is envisioned as a comprehensive approach that integrates DC-based vaccines with state-of-the-art technologies and novel therapeutic strategies. This holistic strategy aims to tackle the challenges posed by the TME and immune evasion mechanisms, ultimately enhancing patient outcomes and opening avenues for further advancements in the field.

Author Contributions

S.Z. and D.G contributed to the writing, reviewing and editing of the review. RDF and AP contributed to reviewing and editing of the review. All authors approved the final version of the manuscript.

Funding

No funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

AP declares lectures honoraria from Hoffmann-La Roche AG, Incyte–Italy, Merck Sharp and Dohme, Bristol-Meyers Squibb, and participation to scientific advisory boards for F. Hoffmann-La Roche AG, Merck Sharp, and Dohme, Takeda, and Incyte-Italy. All other authors have declared no conflicts of interest.

References

  1. Galati, D.; Zanotta, S. Empowering dendritic cell cancer vaccination: the role of combinatorial strategies. Cytotherapy 2018, 20, 1309–1323. [Google Scholar] [CrossRef]
  2. Palucka, K.; Ueno, H.; Roberts, L.; Fay, J.; Banchereau, J. Dendritic cells: are they clinically relevant? Cancer J 2010, 16, 318–324. [Google Scholar] [CrossRef]
  3. Palucka, K.; Banchereau, J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012, 12, 265–277. [Google Scholar] [CrossRef]
  4. Lee, J.H.; Choi, S.Y.; Jung, N.C.; Song, J.Y.; Seo, H.G.; Lee, H.S.; Lim, D.S. The Effect of the Tumor Microenvironment and Tumor-Derived Metabolites on Dendritic Cell Function. J Cancer 2020, 11, 769–775. [Google Scholar] [CrossRef]
  5. Strioga, M.; Schijns, V.; Powell, D.J., Jr.; Pasukoniene, V.; Dobrovolskiene, N.; Michalek, J. Dendritic cells and their role in tumor immunosurveillance. Innate Immun 2013, 19, 98–111. [Google Scholar] [CrossRef]
  6. Galati, D.; Zanotta, S. Hematologic neoplasms: Dendritic cells vaccines in motion. Clin Immunol 2017. [Google Scholar] [CrossRef]
  7. Galati, D.; Zanotta, S.; Bocchino, M.; De Filippi, R.; Pinto, A. The subtle interplay between gamma delta T lymphocytes and dendritic cells: is there a role for a therapeutic cancer vaccine in the era of combinatorial strategies? Cancer Immunol Immunother 2021, 70, 1797–1809. [Google Scholar] [CrossRef]
  8. Ahmed, M.S.; Bae, Y.S. Dendritic cell-based therapeutic cancer vaccines: past, present and future. Clinical and experimental vaccine research 2014, 3, 113–116. [Google Scholar] [CrossRef]
  9. Bol, K.F.; Schreibelt, G.; Gerritsen, W.R.; de Vries, I.J.; Figdor, C.G. Dendritic Cell-Based Immunotherapy: State of the Art and Beyond. Clin Cancer Res 2016, 22, 1897–1906. [Google Scholar] [CrossRef]
  10. Sabado, R.L.; Balan, S.; Bhardwaj, N. Dendritic cell-based immunotherapy. Cell Res 2017, 27, 74–95. [Google Scholar] [CrossRef]
  11. Anguille, S.; Smits, E.L.; Bryant, C.; Van Acker, H.H.; Goossens, H.; Lion, E.; Fromm, P.D.; Hart, D.N.; Van Tendeloo, V.F.; Berneman, Z.N. Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy. Pharmacol Rev 2015, 67, 731–753. [Google Scholar] [CrossRef]
  12. Butterfield, L.H. Dendritic cells in cancer immunotherapy clinical trials: are we making progress? Front Immunol 2013, 4, 454. [Google Scholar] [CrossRef]
  13. Schreibelt, G.; Tel, J.; Sliepen, K.H.E.W.J.; Benitez-Ribas, D.; Figdor, C.G.; Adema, G.J.; de Vries, I.J.M. Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol Immun 2010, 59, 1573–1582. [Google Scholar] [CrossRef]
  14. Cella, M.; Jarrossay, D.; Facchetti, F.; Alebardi, O.; Nakajima, H.; Lanzavecchia, A.; Colonna, M. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med 1999, 5, 919–923. [Google Scholar] [CrossRef]
  15. Ahmed, M.S.; Bae, Y.-S. Dendritic cell-based therapeutic cancer vaccines: past, present and future. Clin Exp Vaccine Res 2014, 3, 113–116. [Google Scholar] [CrossRef]
  16. Tel, J.; Aarntzen, E.H.; Baba, T.; Schreibelt, G.; Schulte, B.M.; Benitez-Ribas, D.; Boerman, O.C.; Croockewit, S.; Oyen, W.J.; van Rossum, M.; et al. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res 2013, 73, 1063–1075. [Google Scholar] [CrossRef]
  17. Prue, R.L.; Vari, F.; Radford, K.J.; Tong, H.; Hardy, M.Y.; D'Rozario, R.; Waterhouse, N.J.; Rossetti, T.; Coleman, R.; Tracey, C.; et al. A phase I clinical trial of CD1c (BDCA-1)+ dendritic cells pulsed with HLA-A*0201 peptides for immunotherapy of metastatic hormone refractory prostate cancer. J Immunother 2015, 38, 71–76. [Google Scholar] [CrossRef]
  18. Schreibelt, G.; Bol, K.F.; Westdorp, H.; Wimmers, F.; Aarntzen, E.H.; Duiveman-de Boer, T.; van de Rakt, M.W.; Scharenborg, N.M.; de Boer, A.J.; Pots, J.M.; et al. Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells. Clin Cancer Res 2016, 22, 2155–2166. [Google Scholar] [CrossRef]
  19. Carreno, B.M.; Magrini, V.; Becker-Hapak, M.; Kaabinejadian, S.; Hundal, J.; Petti, A.A.; Ly, A.; Lie, W.R.; Hildebrand, W.H.; Mardis, E.R.; et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 2015, 348, 803–808. [Google Scholar] [CrossRef]
  20. Kaiser, J. Personalized tumor vaccines keep cancer in check. 2017.
  21. Joseph, C.G.; Darrah, E.; Shah, A.A.; Skora, A.D.; Casciola-Rosen, L.A.; Wigley, F.M.; Boin, F.; Fava, A.; Thoburn, C.; Kinde, I.; et al. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 2014, 343, 152–157. [Google Scholar] [CrossRef]
  22. Chiang, C.L.; Coukos, G.; Kandalaft, L.E. Whole Tumor Antigen Vaccines: Where Are We? Vaccines (Basel) 2015, 3, 344–372. [Google Scholar] [CrossRef]
  23. Gonzalez, F.E.; Gleisner, A.; Falcon-Beas, F.; Osorio, F.; Lopez, M.N.; Salazar-Onfray, F. Tumor cell lysates as immunogenic sources for cancer vaccine design. Hum Vaccin Immunother 2014, 10, 3261–3269. [Google Scholar] [CrossRef]
  24. Schumacher, T.N.; Schreiber, R.D. Neoantigens in cancer immunotherapy. Science 2015, 348, 69–74. [Google Scholar] [CrossRef]
  25. Dougan, M.; Dranoff, G. Immune therapy for cancer. Annu Rev Immunol 2009, 27, 83–117. [Google Scholar] [CrossRef]
  26. Dörrie, J.; Schaft, N.; Schuler, G.; Schuler-Thurner, B. Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells—An Update. 2020, 12, 92.
  27. Beck, J.D.; Reidenbach, D.; Salomon, N.; Sahin, U.; Türeci, Ö.; Vormehr, M.; Kranz, L.M. mRNA therapeutics in cancer immunotherapy. Molecular Cancer 2021, 20, 69. [Google Scholar] [CrossRef]
  28. Guo, C.; Manjili, M.H.; Subjeck, J.R.; Sarkar, D.; Fisher, P.B.; Wang, X.Y. Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res 2013, 119, 421–475. [Google Scholar] [CrossRef]
  29. Galati, D.; Zanotta, S. Hematologic neoplasms: Dendritic cells vaccines in motion. Clin Immunol 2017, 183, 181–190. [Google Scholar] [CrossRef]
  30. Anguille, S.; Smits, E.L.; Lion, E.; van Tendeloo, V.F.; Berneman, Z.N. Clinical use of dendritic cells for cancer therapy. Lancet Oncol 2014, 15, e257–e267. [Google Scholar] [CrossRef]
  31. Ni, M.; Hoffmann, J.M.; Schmitt, M.; Schmitt, A. Progress of dendritic cell-based cancer vaccines for patients with hematological malignancies. Expert opinion on biological therapy 2016, 16, 1113–1123. [Google Scholar] [CrossRef]
  32. Ribas, A.; Comin-Anduix, B.; Chmielowski, B.; Jalil, J.; de la Rocha, P.; McCannel, T.A.; Ochoa, M.T.; Seja, E.; Villanueva, A.; Oseguera, D.K.; et al. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res 2009, 15, 6267–6276. [Google Scholar] [CrossRef]
  33. Datta, J.; Berk, E.; Cintolo, J.A.; Xu, S.; Roses, R.E.; Czerniecki, B.J. Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy. Front Immunol 2015, 6, 271. [Google Scholar] [CrossRef]
  34. Hawkes, E.A.; Grigg, A.; Chong, G. Programmed cell death-1 inhibition in lymphoma. The Lancet. Oncology 2015, 16, e234–e245. [Google Scholar] [CrossRef]
  35. Gong, J.; Chehrazi-Raffle, A.; Reddi, S.; Salgia, R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer 2018, 6, 8. [Google Scholar] [CrossRef]
  36. Chabanon, R.M.; Pedrero, M.; Lefebvre, C.; Marabelle, A.; Soria, J.C.; Postel-Vinay, S. Mutational Landscape and Sensitivity to Immune Checkpoint Blockers. Clin Cancer Res 2016, 22, 4309–4321. [Google Scholar] [CrossRef]
  37. Restifo, N.P.; Smyth, M.J.; Snyder, A. Acquired resistance to immunotherapy and future challenges. Nat Rev Cancer 2016, 16, 121–126. [Google Scholar] [CrossRef]
  38. De Filippi, R.; Marcacci, G.; Derenzini, E.; Musso, M.; Donnarumma, D.; Morelli, E.; Patti, C.; Maraglino, A.M.E.; Scalone, R.; Simeone, L.; et al. Anti-PD1 Consolidation in Patients with Hodgkin Lymphoma at High Risk of Relapse after Autologous Stem Cell Transplantation: A Multicenter Real-Life Study. Cancers (Basel) 2022, 14. [Google Scholar] [CrossRef]
  39. De Filippi, R.; Morabito, F.; Santoro, A.; Tripepi, G.; D'Alo, F.; Rigacci, L.; Ricci, F.; Morelli, E.; Zinzani, P.L.; Pinto, A. Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab. J Transl Med 2021, 19, 489. [Google Scholar] [CrossRef]
  40. Larkin, J.; Hodi, F.S.; Wolchok, J.D. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015, 373, 1270–1271. [Google Scholar] [CrossRef]
  41. Chen, D.S.; Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature 2017, 541, 321–330. [Google Scholar] [CrossRef]
  42. Sharma, P.; Allison, J.P. The future of immune checkpoint therapy. Science 2015, 348, 56–61. [Google Scholar] [CrossRef]
  43. Brown, S.D.; Warren, R.L.; Gibb, E.A.; Martin, S.D.; Spinelli, J.J.; Nelson, B.H.; Holt, R.A. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res 2014, 24, 743–750. [Google Scholar] [CrossRef]
  44. Roemer, M.G.; Advani, R.H.; Ligon, A.H.; Natkunam, Y.; Redd, R.A.; Homer, H.; Connelly, C.F.; Sun, H.H.; Daadi, S.E.; Freeman, G.J.; et al. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. J Clin Oncol 2016, 34, 2690–2697. [Google Scholar] [CrossRef]
  45. Chapuy, B.; Stewart, C.; Dunford, A.J.; Kim, J.; Wienand, K.; Kamburov, A.; Griffin, G.K.; Chen, P.H.; Lako, A.; Redd, R.A.; et al. Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade. Blood 2019, 134, 2369–2382. [Google Scholar] [CrossRef]
  46. Armand, P.; Engert, A.; Younes, A.; Fanale, M.; Santoro, A.; Zinzani, P.L.; Timmerman, J.M.; Collins, G.P.; Ramchandren, R.; Cohen, J.B.; et al. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol 2018, 36, 1428–1439. [Google Scholar] [CrossRef]
  47. Zinzani, P.L.; Thieblemont, C.; Melnichenko, V.; Bouabdallah, K.; Walewski, J.; Majlis, A.; Fogliatto, L.; Garcia-Sancho, A.M.; Christian, B.; Gulbas, Z.; et al. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170. Blood 2023, 142, 141–145. [Google Scholar] [CrossRef]
  48. Hsu, J.L.; Bryant, C.E.; Papadimitrious, M.S.; Kong, B.; Gasiorowski, R.E.; Orellana, D.; McGuire, H.M.; Groth, B.F.d.S.; Joshua, D.E.; Ho, P.J.; et al. A blood dendritic cell vaccine for acute myeloid leukemia expands anti-tumor T cell responses at remission. OncoImmunology 2018, 7, e1419114. [Google Scholar] [CrossRef]
  49. Zhong, R.K.; Loken, M.; Lane, T.A.; Ball, E.D. CTLA-4 blockade by a human MAb enhances the capacity of AML-derived DC to induce T-cell responses against AML cells in an autologous culture system. Cytotherapy 2006, 8, 3–12. [Google Scholar] [CrossRef]
  50. Wilgenhof, S.; Corthals, J.; Heirman, C.; van Baren, N.; Lucas, S.; Kvistborg, P.; Thielemans, K.; Neyns, B. Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma. J Clin Oncol 2016, 34, 1330–1338. [Google Scholar] [CrossRef]
  51. Liu, L.; Wang, Y.; Miao, L.; Liu, Q.; Musetti, S.; Li, J.; Huang, L. Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer. Mol Ther 2018, 26, 45–55. [Google Scholar] [CrossRef]
  52. Nagaoka, K.; Hosoi, A.; Iino, T.; Morishita, Y.; Matsushita, H.; Kakimi, K. Dendritic cell vaccine induces antigen-specific CD8<SUP>+</SUP> T cells that are metabolically distinct from those of peptide vaccine and is well-combined with PD-1 checkpoint blockade. Oncoimmunology 2018, 7. doi:ARTN e1395124. [Google Scholar]
  53. 10. 2017.139 5124.
  54. Kodumudi, K.N.; Ramamoorthi, G.; Snyder, C.; Basu, A.; Jia, Y.; Awshah, S.; Beyer, A.P.; Wiener, D.; Lam, L.; Zhang, H.; et al. Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response. 2019, 10. [CrossRef]
  55. Antonios, J.P.; Soto, H.; Everson, R.G.; Orpilla, J.; Moughon, D.; Shin, N.; Sedighim, S.; Yong, W.H.; Li, G.; Cloughesy, T.F.; et al. PD-1 blockade enhances the vaccination-induced immune response in glioma. JCI Insight 2016, 1. [Google Scholar] [CrossRef]
  56. Rosenblatt, J.; Glotzbecker, B.; Mills, H.; Vasir, B.; Tzachanis, D.; Levine, J.D.; Joyce, R.M.; Wellenstein, K.; Keefe, W.; Schickler, M.; et al. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother 2011, 34, 409–418. [Google Scholar] [CrossRef]
  57. Nesselhut, J.; Marx, D.; Lange, H.; Regalo, G.; Cillien, N.; Chang, R.Y.; Nesselhut, T. Systemic treatment with anti-PD-1 antibody nivolumab in combination with vaccine therapy in advanced pancreatic cancer. J Clin Oncol 2016, 34. [Google Scholar] [CrossRef]
  58. Hu, Z.; Ma, Y.; Shang, Z.; Hu, S.; Liang, K.; Liang, W.; Xing, X.; Wang, Y.; Du, X. Improving immunotherapy for colorectal cancer using dendritic cells combined with anti-programmed death-ligand in vitro. Oncol Lett 2018, 15, 5345–5351. [Google Scholar] [CrossRef]
  59. Pen, J.J.; Keersmaecker, B.D.; Heirman, C.; Corthals, J.; Liechtenstein, T.; Escors, D.; Thielemans, K.; Breckpot, K. Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells. Gene Therapy 2014, 21, 262–271. [Google Scholar] [CrossRef]
  60. Hobo, W.; Maas, F.; Adisty, N.; de Witte, T.; Schaap, N.; van der Voort, R.; Dolstra, H. siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen–specific CD8+ T cells. Blood 2010, 116, 4501–4511. [Google Scholar] [CrossRef]
  61. Kourie, H.R.; Klastersky, J. Immune checkpoint inhibitors side effects and management. Immunotherapy 2016, 8, 799–807. [Google Scholar] [CrossRef]
  62. Garg, A.D.; Coulie, P.G.; Van den Eynde, B.J.; Agostinis, P. Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape. Trends Immunol 2017, 38, 577–593. [Google Scholar] [CrossRef]
  63. Rosenblatt, J.; Stone, R.M.; Uhl, L.; Neuberg, D.; Joyce, R.; Levine, J.D.; Arnason, J.; McMasters, M.; Luptakova, K.; Jain, S.; et al. Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions. Sci Transl Med 2016, 8, 368ra171. [Google Scholar] [CrossRef]
  64. Woo, S.R.; Turnis, M.E.; Goldberg, M.V.; Bankoti, J.; Selby, M.; Nirschl, C.J.; Bettini, M.L.; Gravano, D.M.; Vogel, P.; Liu, C.L.; et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012, 72, 917–927. [Google Scholar] [CrossRef]
  65. Sakuishi, K.; Apetoh, L.; Sullivan, J.M.; Blazar, B.R.; Kuchroo, V.K.; Anderson, A.C. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. The Journal of experimental medicine 2010, 207, 2187–2194. [Google Scholar] [CrossRef]
  66. Zhou, Q.; Munger, M.E.; Veenstra, R.G.; Weigel, B.J.; Hirashima, M.; Munn, D.H.; Murphy, W.J.; Azuma, M.; Anderson, A.C.; Kuchroo, V.K.; et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 2011, 117, 4501–4510. [Google Scholar] [CrossRef]
  67. Romano, E.; Michielin, O.; Voelter, V.; Laurent, J.; Bichat, H.; Stravodimou, A.; Romero, P.; Speiser, D.E.; Triebel, F.; Leyvraz, S.; et al. MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial. J Transl Med 2014, 12, 97. [Google Scholar] [CrossRef]
  68. Lichtenegger, F.S.; Rothe, M.; Schnorfeil, F.M.; Deiser, K.; Krupka, C.; Augsberger, C.; Schlüter, M.; Neitz, J.; Subklewe, M. Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells. 2018, 9. [CrossRef]
  69. Lu, X.; Liu, J.; Cui, P.; Liu, T.; Piao, C.; Xu, X.; Zhang, Q.; Xiao, M.; Liu, X.; Wang, Y.; et al. Co-inhibition of TIGIT, PD1, and Tim3 reverses dysfunction of Wilms tumor protein-1 (WT1)-specific CD8+ T lymphocytes after dendritic cell vaccination in gastric cancer. Am J Cancer Res 2018, 8, 1564–1575. [Google Scholar]
  70. Till, B.G.; Jensen, M.C.; Wang, J.; Chen, E.Y.; Wood, B.L.; Greisman, H.A.; Qian, X.; James, S.E.; Raubitschek, A.; Forman, S.J.; et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008, 112, 2261–2271. [Google Scholar] [CrossRef]
  71. Kochenderfer, J.N.; Wilson, W.H.; Janik, J.E.; Dudley, M.E.; Stetler-Stevenson, M.; Feldman, S.A.; Maric, I.; Raffeld, M.; Nathan, D.A.; Lanier, B.J.; et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010, 116, 4099–4102. [Google Scholar] [CrossRef]
  72. Slaney, C.Y.; von Scheidt, B.; Davenport, A.J.; Beavis, P.A.; Westwood, J.A.; Mardiana, S.; Tscharke, D.C.; Ellis, S.; Prince, H.M.; Trapani, J.A.; et al. Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting. Clin Cancer Res 2017, 23, 2478–2490. [Google Scholar] [CrossRef]
Preprints 109088 g001
Figure 1. Combinatorial strategies. The figure 1 systematically summarizes the use of immune checkpoint inhibitors based on the different therapeutic mechanisms, as combinatorial strategies to optimization of DCs-based cancer vaccine.
Figure 1. Combinatorial strategies. The figure 1 systematically summarizes the use of immune checkpoint inhibitors based on the different therapeutic mechanisms, as combinatorial strategies to optimization of DCs-based cancer vaccine.
Preprints 109088 g001
Preprints 109088 g002
Figure 2. Multimodal enhancement of dc-based cancer vaccines. The figure 2 demonstrates how combinatorial therapy with (ICIs) can enhance DC cancer vaccination. Checkpoint inhibitors are designed to augment the immune effector response and counteract immunosuppressive pathways. By synergizing DC-based cancer vaccines with engineered T cells, this approach can significantly amplify T cell responses against TAAs, leading to a more effective and targeted anti-tumor immune response.
Figure 2. Multimodal enhancement of dc-based cancer vaccines. The figure 2 demonstrates how combinatorial therapy with (ICIs) can enhance DC cancer vaccination. Checkpoint inhibitors are designed to augment the immune effector response and counteract immunosuppressive pathways. By synergizing DC-based cancer vaccines with engineered T cells, this approach can significantly amplify T cell responses against TAAs, leading to a more effective and targeted anti-tumor immune response.
Preprints 109088 g002
Table 1. Active clinical trials combinatorial strategies. An organised summary of ongoing clinical trials on DCs-based cancer vaccines with combination strategies.
Table 1. Active clinical trials combinatorial strategies. An organised summary of ongoing clinical trials on DCs-based cancer vaccines with combination strategies.
Study ID Therapeutic Strategy Condition/Disease Phase Status
NCT01067287 CT-011 alone, or plus DC fusion vaccine after ASCT MM II Active, not recruiting
NCT02528682 MiHA-loaded PD-L-silenced DC Vaccination after allo-SCT Hematological Malignancies I/II Completed
NCT01096602 Blockade of PD-1 plus DC/AML Vaccine after Chemotherapy AML II Active, not recruiting
NCT03035331 Intratumorally DC vaccine After Cryoablation and Pembrolizumab LNH I/II Active, not recruiting
NCT03325101 Intratumorally Autologous DC vaccine after Cryoablation plus Pembrolizumab Melanoma I/II Active, not recruiting
NCT02677155 Sequential Intranodal Immunotherapy (SIIT) plus Pembrolizumab FLC II Completed
NCT05631886 Intratumorally Autologous DC vaccine plus Cryoablation and Pembrolizumab LNH I/II Active, not recruiting
AML: Acute Myeloid Leukemia; MM: Multiple Myeloma.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2024 MDPI (Basel, Switzerland) unless otherwise stated